GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » EV-to-EBIT

RenovaCare (RenovaCare) EV-to-EBIT : 0.00 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is RenovaCare EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RenovaCare's Enterprise Value is $0.00 Mil. RenovaCare's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.68 Mil. Therefore, RenovaCare's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for RenovaCare's EV-to-EBIT or its related term are showing as below:

RCAR's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.19
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RenovaCare's Enterprise Value for the quarter that ended in Sep. 2022 was $5.16 Mil. RenovaCare's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.68 Mil. RenovaCare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -129.33%.


RenovaCare EV-to-EBIT Historical Data

The historical data trend for RenovaCare's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare EV-to-EBIT Chart

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -137.01 -55.89 -72.45 -24.52 -3.99

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.99 -3.99 -3.14 -0.78 -0.77

Competitive Comparison of RenovaCare's EV-to-EBIT

For the Biotechnology subindustry, RenovaCare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovaCare's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovaCare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RenovaCare's EV-to-EBIT falls into.



RenovaCare EV-to-EBIT Calculation

RenovaCare's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-6.677
=0.00

RenovaCare's current Enterprise Value is $0.00 Mil.
RenovaCare's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare  (OTCPK:RCAR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RenovaCare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-6.677/5.16270764
=-129.33 %

RenovaCare's Enterprise Value for the quarter that ended in Sep. 2022 was $5.16 Mil.
RenovaCare's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of RenovaCare's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovaCare (RenovaCare) Business Description

Traded in Other Exchanges
N/A
Address
9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Executives
Patsy Trisler officer: Vice President 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold officer: President & CEO 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen director, officer: President & CEO 43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd. 10 percent owner 1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins director 406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace director, officer: President CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu director 5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper officer: President/ CEO
Frank J Fabio officer: CFO/Sec.(Resigned 1/9/2009) 670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson director 33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat director, 10 percent owner 700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong officer: President/CEO
Terri Dumoulin director, officer: Secretary/Treasurer

RenovaCare (RenovaCare) Headlines

From GuruFocus